CD269. also known as B-cell maturation antigen (BCMA), is a transmembrane protein encoded by the TNFRSF17 gene and belongs to the tumor necrosis factor receptor superfamily. It is primarily expressed on plasma cells and certain B-cell subsets, playing a critical role in B-cell development, survival, and immune regulation. BCMA binds to two ligands, BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), which activate signaling pathways like NF-κB, promoting cell proliferation and inhibiting apoptosis. Dysregulation of BCMA is implicated in hematologic malignancies, particularly multiple myeloma (MM), where its overexpression supports malignant plasma cell survival.
CD269 antibodies are therapeutic or diagnostic tools targeting this antigen. In MM therapy, anti-CD269 monoclonal antibodies (e.g., belantamab mafodotin) are designed as antibody-drug conjugates (ADCs) or bispecific antibodies to selectively eliminate malignant cells. Belantamab mafodotin, an ADC approved by the FDA in 2020. delivers a cytotoxic payload to BCMA-expressing cells. Bispecific antibodies, such as those engaging CD3 on T-cells, redirect immune cells to attack tumors. Additionally, BCMA is a key target in chimeric antigen receptor (CAR) T-cell therapies, showing remarkable efficacy in relapsed/refractory MM.
Research continues to optimize CD269-targeted therapies, addressing challenges like antigen escape and toxicity. These advancements highlight BCMA's significance in precision oncology and immunotherapy for B-cell malignancies.